Prognostic value of a novel glycolysis-related gene expression signature for gastrointestinal cancer in the Asian population.
Asian patients
Gastrointestinal cancer
Glycolysis-related genes
Prognosis
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
04 Mar 2021
04 Mar 2021
Historique:
received:
28
12
2020
accepted:
24
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Globally, gastrointestinal (GI) cancer is one of the most prevalent malignant tumors. However, studies have not established glycolysis-related gene signatures that can be used to construct accurate prognostic models for GI cancers in the Asian population. Herein, we aimed at establishing a novel glycolysis-related gene expression signature to predict the prognosis of GI cancers. First, we evaluated the mRNA expression profiles and the corresponding clinical data of 296 Asian GI cancer patients in The Cancer Genome Atlas (TCGA) database (TCGA-LIHC, TCGA-STAD, TCGA-ESCA, TCGA-PAAD, TCGA-COAD, TCGA-CHOL and TCGA-READ). Differentially expressed mRNAs between GI tumors and normal tissues were investigated. Gene Set Enrichment Analysis (GSEA) was performed to identify glycolysis-related genes. Then, univariate, LASSO regression and multivariate Cox regression analyses were performed to establish a key prognostic glycolysis-related gene expression signature. The Kaplan-Meier and receiver operating characteristic (ROC) curves were used to evaluate the efficiency and accuracy of survival prediction. Finally, a risk score to predict the prognosis of GI cancers was calculated and validated using the TCGA data sets. Furthermore, this risk score was verified in two Gene Expression Omnibus (GEO) data sets (GSE116174 and GSE84433) and in 28 pairs of tissue samples. Prognosis-related genes (NUP85, HAX1, GNPDA1, HDLBP and GPD1) among the differentially expressed glycolysis-related genes were screened and identified. The five-gene expression signature was used to assign patients into high- and low-risk groups (p < 0.05) and it showed a satisfactory prognostic value for overall survival (OS, p = 6.383 × 10 Based on the five glycolysis-related genes (NUP85, HAX1, GNPDA1, HDLBP and GPD1), and in combination with clinical characteristics, this model can independently predict the OS of GI cancers in Asian patients.
Sections du résumé
BACKGROUND
BACKGROUND
Globally, gastrointestinal (GI) cancer is one of the most prevalent malignant tumors. However, studies have not established glycolysis-related gene signatures that can be used to construct accurate prognostic models for GI cancers in the Asian population. Herein, we aimed at establishing a novel glycolysis-related gene expression signature to predict the prognosis of GI cancers.
METHODS
METHODS
First, we evaluated the mRNA expression profiles and the corresponding clinical data of 296 Asian GI cancer patients in The Cancer Genome Atlas (TCGA) database (TCGA-LIHC, TCGA-STAD, TCGA-ESCA, TCGA-PAAD, TCGA-COAD, TCGA-CHOL and TCGA-READ). Differentially expressed mRNAs between GI tumors and normal tissues were investigated. Gene Set Enrichment Analysis (GSEA) was performed to identify glycolysis-related genes. Then, univariate, LASSO regression and multivariate Cox regression analyses were performed to establish a key prognostic glycolysis-related gene expression signature. The Kaplan-Meier and receiver operating characteristic (ROC) curves were used to evaluate the efficiency and accuracy of survival prediction. Finally, a risk score to predict the prognosis of GI cancers was calculated and validated using the TCGA data sets. Furthermore, this risk score was verified in two Gene Expression Omnibus (GEO) data sets (GSE116174 and GSE84433) and in 28 pairs of tissue samples.
RESULTS
RESULTS
Prognosis-related genes (NUP85, HAX1, GNPDA1, HDLBP and GPD1) among the differentially expressed glycolysis-related genes were screened and identified. The five-gene expression signature was used to assign patients into high- and low-risk groups (p < 0.05) and it showed a satisfactory prognostic value for overall survival (OS, p = 6.383 × 10
CONCLUSIONS
CONCLUSIONS
Based on the five glycolysis-related genes (NUP85, HAX1, GNPDA1, HDLBP and GPD1), and in combination with clinical characteristics, this model can independently predict the OS of GI cancers in Asian patients.
Identifiants
pubmed: 33663535
doi: 10.1186/s12935-021-01857-4
pii: 10.1186/s12935-021-01857-4
pmc: PMC7934443
doi:
Types de publication
Journal Article
Langues
eng
Pagination
154Subventions
Organisme : National Natural Science Foundation of China
ID : 81903353
Organisme : the Technology Development Fund of Nanjing Medical University
ID : NMUB2018001
Organisme : the project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions and the Collegiate Natural Science Foundation of Jiangsu Province
ID : 19KJB330003
Organisme : the Scientific Research Funding of Tongling Municipal Health Commission
ID : 201912
Références
Int J Mol Sci. 2019 Dec 11;20(24):
pubmed: 31835815
Chemosphere. 2020 May;246:125774
pubmed: 31901531
Am J Hum Genet. 2012 Jan 13;90(1):49-60
pubmed: 22226083
Ann Transl Med. 2020 Mar;8(6):279
pubmed: 32355723
Oncogenesis. 2019 Mar 8;8(3):21
pubmed: 30850580
Nat Commun. 2020 Apr 20;11(1):1869
pubmed: 32313017
Genes Dev. 2013 Oct 1;27(19):2065-71
pubmed: 24115766
Eur J Hum Genet. 2014 Oct;22(10):1229-32
pubmed: 24549054
Aging (Albany NY). 2020 Nov 26;13(1):675-693
pubmed: 33260154
Mol Oncol. 2020 Mar;14(3):539-555
pubmed: 31901148
Cell Death Dis. 2020 May 11;11(5):355
pubmed: 32393782
Cell Stem Cell. 2019 Aug 1;25(2):241-257.e8
pubmed: 31303549
Oncol Rep. 2014 May;31(5):2328-34
pubmed: 24676454
Theranostics. 2019 Jan 24;9(3):796-810
pubmed: 30809309
Cancer Med. 2020 Oct;9(19):7231-7243
pubmed: 32780563
Liver Cancer. 2018 Sep;7(3):277-294
pubmed: 30319985
Stem Cells. 2018 Mar;36(3):406-419
pubmed: 29139175
Carcinogenesis. 2008 Jun;29(6):1235-43
pubmed: 18413364
Med Res Rev. 2012 Jul;32(4):687-726
pubmed: 22549716
JCI Insight. 2020 Mar 12;5(5):
pubmed: 32053518
Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):377-397
pubmed: 31467232
Cancer Cell Int. 2020 Oct 12;20:503
pubmed: 33061855
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4
pubmed: 18692501
Glycobiology. 2016 Jul;26(7):710-22
pubmed: 26887390
Autophagy. 2019 May;15(5):886-899
pubmed: 30782064
Elife. 2016 Oct 19;5:
pubmed: 27759563
Cell. 2016 Dec 15;167(7):1803-1813.e12
pubmed: 27984728
Cancer Manag Res. 2020 Jun 24;12:4923-4935
pubmed: 32606980
Carcinogenesis. 2014 Jul;35(7):1441-50
pubmed: 24743516
Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70
pubmed: 18838122
Cancer Sci. 2019 Aug;110(8):2368-2377
pubmed: 31222863
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8
pubmed: 21205897
Cancers (Basel). 2020 Jul 04;12(7):
pubmed: 32635458
BMC Cancer. 2019 Dec 30;19(1):1260
pubmed: 31888560
World J Gastroenterol. 2014 Sep 7;20(33):11840-9
pubmed: 25206290
PeerJ. 2020 Sep 29;8:e9944
pubmed: 33062428
Mol Cell Biochem. 2005 Jul;275(1-2):25-55
pubmed: 16335783
Mol Cancer. 2019 Dec 2;18(1):174
pubmed: 31791342
Oncogenesis. 2016 May 09;5:e224
pubmed: 27159677
Redox Biol. 2019 Apr;22:101149
pubmed: 30822690
Antioxid Redox Signal. 2010 Dec 1;13(11):1713-48
pubmed: 20446772
Biosci Rep. 2020 Aug 28;40(8):
pubmed: 32744303
J Gastroenterol Hepatol. 2009 Jun;24(6):955-61
pubmed: 19383082
PLoS Med. 2010 Jul 13;7(7):e1000307
pubmed: 20644708
Oncotarget. 2016 Apr 19;7(16):22092-102
pubmed: 26989077
J Cell Biochem. 2003 Apr 1;88(5):932-40
pubmed: 12616532
J Clin Invest. 2018 Oct 1;128(10):4313-4328
pubmed: 30179222
Genomics. 2004 Jun;83(6):1024-45
pubmed: 15177556
Aging (Albany NY). 2020 Jun 1;12(11):10300-10316
pubmed: 32479426
J Immunother Cancer. 2019 Oct 21;7(1):268
pubmed: 31639056
Cancer Res. 2020 Apr 15;80(8):1630-1643
pubmed: 31911550
Cancer Res. 2010 Jul 1;70(13):5486-96
pubmed: 20530669
Cancer Res. 2014 Dec 15;74(24):7430-41
pubmed: 25339352
Cells. 2019 Dec 19;9(1):
pubmed: 31861674
Trends Mol Med. 2016 Jul;22(7):578-593
pubmed: 27263465
Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):99-106
pubmed: 16487042
Biochim Biophys Acta. 2013 Mar;1827(3):401-10
pubmed: 23220394
Nat Rev Mol Cell Biol. 2017 Feb;18(2):73-89
pubmed: 27999437
Nat Med. 2014 Dec;20(12):1401-9
pubmed: 25419709
Nat Rev Cancer. 2016 Nov;16(11):749
pubmed: 28704361
Int J Mol Sci. 2020 Apr 06;21(7):
pubmed: 32268527
FEBS Lett. 2003 Sep 11;551(1-3):63-70
pubmed: 12965206
J Cell Mol Med. 2020 Apr;24(7):3807-3821
pubmed: 32065482
Cancer Lett. 2020 Jun 1;479:112-122
pubmed: 32200037
Cell. 2019 May 2;177(4):1035-1049.e19
pubmed: 31031003
Front Pharmacol. 2018 May 15;9:502
pubmed: 29867504
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
FASEB J. 1998 Jan;12(1):91-9
pubmed: 9438414
Oxid Med Cell Longev. 2019 Oct 8;2019:7831952
pubmed: 31687086
Cell Death Dis. 2020 Oct 23;11(10):902
pubmed: 33097691
Genes Dev. 2021 Feb 1;35(3-4):218-233
pubmed: 33446568
Cancer Res. 2020 Jun 1;80(11):2150-2162
pubmed: 32179514
J Chromatogr A. 2008 Jun 13;1194(1):3-10
pubmed: 18407281
Cancer Cell Int. 2020 Mar 14;20:80
pubmed: 32190004
Oncotarget. 2017 Sep 19;8(60):101309-101324
pubmed: 29254166
J Cancer Res Clin Oncol. 2019 Apr;145(4):967-999
pubmed: 30825027
Nat Commun. 2020 Jan 10;11(1):192
pubmed: 31924791